Sanofi Q1 FY26 Earnings Analysis

- For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, continuing profitable growth over at least 5 years. (Page 16) - Long-term ambition includes pursuing earnings growth into the next decade based on pipeline and external growth opportunities. (Page 16) - Vaccine sales are expected to slightly decline in 2026 amid ongoing portfolio optimization. (Page 3) - Strong growth drivers include expansion of Dupixent with multiple indications and new medicine launches like Qfitlia, Wayrilz, and Nuvaxovid. (Pages 2, 16) - Pipeline advancements with promising assets (e.g., amlitelimab, gene therapies), plus business development firepower of €14-15 billion for strategic acquisitions, primarily focused on Phase I and II assets. (Pages 14, 3) - Expectation of continued volume growth, especially in immunology and vaccine expansions outside the U.S. (Page 6)

- In 2026, Sanofi expects sales to grow by a high single-digit percentage. - Business EPS (Earnings Per Share) is anticipated to grow slightly faster than sales in 2026. - Profitable growth is projected to continue for at least 5 years from 2025 onwards. - The company aims to pursue earnings growth into the next decade, supported by its pipeline and external growth opportunities. - For 2026, the outlook includes: - Sales growth close to 2025’s performance (9.9% in 2025). - Operating income to include around EUR 500 million of capital gains from disposals. - Stable effective tax rate. - Sanofi targets sustainable free cash flow of at least 20% of net sales in the medium term, up from 18.5% in 2025. - The company plans disciplined capital allocation aimed at long-term returns rather than short-term growth chasing.

- In 2025, Sanofi significantly increased organic growth investments in R&D, commercial capabilities, CapEx, and digital transformation to fuel current and future growth. - They deployed proceeds from the Opella divestment into strategic acquisitions such as Blueprint, Vicebio, Dren Bio DR-0201, and Vigil to accelerate transformation. - Moderate increase expected in underlying R&D expenses for 2026, alongside added placeholder for potential future acquisitions, particularly Phase I and II assets. - Sales and marketing expenses will rise in 2026 to support growth and launches. - Stable G&A expenses targeted in 2026. - A EUR 1 billion share buyback program is planned for 2026, continuing capital allocation policy focused on sustainable value creation and shareholder returns while investing in long-term growth opportunities. - Continued portfolio optimization via divestments expected, reducing sales by approx. EUR 200 million in 2026. - Operating income to include around EUR 500 million of capital gains from disposals in 2026.

- Sanofi ended 2025 with a strong capital structure and low net debt of EUR 11 billion. - Maintained a conservative net debt-to-EBITDA ratio of 0.8x, supporting financial flexibility. - The company has significant financial flexibility for future external growth opportunities while maintaining its AA rating. - No specific mentions of new fundraising through debt or equity in 2026; instead, focus on disciplined capital allocation and use of existing financial resources. - Planned to execute a EUR 1 billion share buyback program in 2026, continuing shareholder returns. - Increased R&D investments and placeholder for potential future acquisitions, funded through existing resources and cash flow. - Emphasis is on disciplined and strategic use of capital without explicit plans for new debt or equity issuance announced.

The provided transcript does not explicitly mention current or expected orderbook or pending orders figures for Sanofi. However, relevant financial and business outlook details related to growth and pipelines include: - In 2025, Sanofi achieved strong profitable growth, with sales increasing by 9.9% and business EPS growing by 15%. - For 2026, sales are expected to grow by a high single-digit percentage, with business EPS growing slightly faster than sales. - Continued profitable growth is anticipated over at least the next 5 years. - The company is targeting strong free cash flow generation (at least 20% of net sales medium-term) with disciplined inventory management. - Sales dynamics in 2026 include portfolio optimization with divestments reducing sales by about EUR 200 million. - A EUR 1 billion share buyback program is planned for 2026, indicating capital allocation strength. - Pipeline advancements and regulatory approvals are expected to support future order inflows. No specific pending order backlog figures disclosed.